{"id":"W4409907961","doi":"10.1158/1078-0432.ccr-25-0073","title":"INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research","funders":"EMD Serono; Genentech; Qbiotics; Ipsen; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Servier; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; Coherus Biosciences; Rakuten Medical; BeiGene; Relay Therapeutics; Seagen; Agios Pharmaceuticals; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Sanofi; Exelixis; Directorate for Biological Sciences; GlaxoSmithKline; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Cetuximab; Medicine; Head and neck; Head and neck squamous-cell carcinoma; Basal cell; Head and neck cancer; Oncology; Placebo; Phases of clinical research; Internal medicine; Cancer; Pathology; Chemotherapy; Surgery; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002366064,0.001891905,0.002259001,0.0006894844,0.0006813133,0.001334415,0.001384724,0.002238618,0.005539909],"category_scores_gemma":[0.001693097,0.0008452201,0.001373563,0.0004474178,0.001187713,0.001183942,0.0005645803,0.003158813,0.001188511],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001007512,"about_ca_system_score_gemma":0.001492714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001018432,"about_ca_topic_score_gemma":0.003382859,"domain_scores_codex":[0.9992111,0.0004298677,0.00004518587,0.0001359924,0.00008561421,0.00009223281],"domain_scores_gemma":[0.9991778,0.0001725063,0.0002636783,0.00005527716,0.00005841985,0.0002724036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9493946,0.02263214,0.000757054,0.001186087,0.001097067,0.00003850403,0.00008654589,0.0003242289,0.005935552,0.0001244141,0.001212189,0.01721171],"study_design_scores_gemma":[0.9441539,0.05306078,0.00119153,0.00002561936,0.0002784149,0.00002103064,0.00001239524,0.0002455222,0.0004624957,0.00005076573,0.0004870468,0.00001050578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774985,0.008270551,0.001040995,0.0008875732,0.000598304,0.00748624,0.001368658,0.0003483223,0.002500892],"genre_scores_gemma":[0.977711,0.004125139,0.002479788,0.001563477,0.0005491361,0.008283019,0.001334722,0.00004668338,0.003906931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005539909,"threshold_uncertainty_score":0.01853287,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.148584438661407,"score_gpt":0.5159044063151957,"score_spread":0.3673199676537887,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}